HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

NCT07462923 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: HS-20093 for injection

Sponsor

Hansoh BioMedical R&D Company